In breast cancer, overexpression of LAPTM4B leads to the sequestration of anthracycline, delaying its concentration in the nucleus, thereby inducing anthracycline resistance and ultimately breast cancer recurrence and metastasis [14]. Here, LAPTM4B is linked to breast carcinoma.